NEW ORLEANS—“Ocrelizumab is the first in- vestigational treatment to reach primary and key
secondary efficacy end points in a phase III primary
progressive MS [PPMS] study,” reported Jerry S. Wolinsky, MD, Bartels Family Professor and Opal C. Rankin
Professor in Neurology at the University of Texas Health
Science Center at Houston. On behalf of his study collaborators, Dr. Wolinsky presented the results from a
subgroup analysis of the ORATORIO study at the ACTRIMS 2016 Forum.
Consistent with other PPMS study populations, OR-
ATORIO study patients included several individuals
with T1 gadolinium-enhancing lesions at baseline. “The
efficacy of ocrelizumab versus placebo in patients with
and without gadolinium–positive lesions at baseline was
consistent with what was seen in the overall study popu-
lation,” Dr. Wolinsky concluded.
Ocrelizumab is a humanized monoclonal antibody
that selectively targets and depletes CD20+ B cells. In
ORATORIO, a randomized, double-blind, placebo-controlled phase III trial, ocrelizumab significantly
reduced disease activity in patients with PPMS. Further, ORATORIO was the first major clinical trial in
PPMS to achieve positive results. The main study
April 2016
Volume 24, Number 4
ORATORIO Subgroup Analysis
Looks at Baseline Enhancement
Activity’s Effect on Outcome
Serving the Neurology Community Since 1993
FOLLOW US ON Find us on
facebook
continued on page 3
Should Insulin Resistance
4 Be Treated to Prevent Stroke?
Use of Endovascular
13 Thrombectomy Is on the Rise
The Benefits and Limitations
16 of Laser Ablation
Potential Targets for
29 Progressive MS Therapy
An Alternative Path Toward
32 Maintenance of Certification
Mobile Stroke Treatment
36 Units Tested in Cleveland
Headache Outcomes After IV
40 DHE for Chronic Miraine
Inside This Issue
©
ISM
/Ph
oto
ta
ke
